Peptide Therapeutics Forum 2014 (MipTec)

Peptide Therapeutics Forum 2014 (MipTec)

Aim of the forum: disseminate information on latest developments & enable networking of interested parties from academia and industries.

Start Date 23.09.2014 - 08:30
Event End 23.09.2014 - 17:00
Location Congress Center Basel

The Peptide Therapeutics Forum 2014 will be divided up in a morning session on “Peptide Discovery” and afternoon presentations on “Development of therapeutic Peptides”. The first part provides some insight into latest methodologies for peptide synthesis and interesting projects more from a preclinical perspective. The afternoon session is dedicated to more advanced peptides. Topics to be discussed include intracellular delivery of peptides, diagnostic imaging and specific disease associated themes, e.g. peptides from the Incretin family to treat diabetes & obesity. This event is thought to disseminate information on latest developments in the broad field of therapeutic peptides and to enable networking of interested parties from academia and industries.

Flyer Peptide Therapeutics Forum, Spt 23, 2014

Confirmed Speakers:

  • Prof. Fernando Albericio, IRB - Institute for Research in Biomedicine, «Cyclic Peptides from the Nature to the Synthetic Ones»
  • Dr. Peter Timmerman, Pepscan Therapeutics, «2-Clips Peptides: A novel Class of Biopharmaceuticals»
  • Dr. Jigar Patel, Roche Diagnostics GmbH, «High-density synthetic peptide arrays as a tool for de-novo High-Quality lead generation in peptide and peptide drug candidate discovery»
  • Prof. Jeffrey Bode, Swiss Federal Institute of Technology, «Simple Synthesis of Macrocyclic Peptides with the KAHA Ligation»
  • Dr. Paul Watt, Phylogica Ltd., «Phylomer libraries as a rich source of peptides for efficient delivery to the cytoplasm»
  • Prof. John D. Wade, Florey Institute for Neuroscience & Mental Health, «Relaxin Family peptides: new members, new functions and potential clinical applications»
  • Dr. David Rozema, Arrowhead Research, «Peptide-based vehicles for siRNA delivery in vivo: ARC-520 in clinical development for the treatment of HBV
  • Prof. Dr. Hans-J Wester, Technische Universität München, «Development, evaluation and first clinical data with CXCR4 targeted peptides»
  • Dr. Gert Moll, Lanthio Pharma, «GPCR-specific lanthionine-stabilized peptide therapeutics»

  

Contact:

Thomas Vorherr, Novartis Pharma AG (Basel, CH)
Eric Kitas, F. Hoffmann-La Roche (Basel, CH)